argenx SE To Present New Data From Phase 3 Study Evaluating VYVGART Hytrulo In Patients With Autoimmune Myositis, Focused On IMNM And DM, At ACR Convergence 2026

Benzinga

2026.10.19 12:07 (GMT+0)

Benzingaで開く